SOURCE: Paragon Financial Limited

Paragon Financial Limited

December 12, 2011 08:16 ET

Genta Incorporated and Cell Therapeutics -- Poised for Growth in 2012

The Paragon Report Provides Equity Research on Genta Incorporated & Cell Therapeutics

NEW YORK, NY--(Marketwire - Dec 12, 2011) - The biotechnology industry has performed well in 2011 as mergers and acquisitions and favorable legislation have propped up the sector. The domestic biotechnology industry has tapped into only a fraction of its several potential applications and is expected to grow to $146.2 billion in 2016, from an estimated $92.4 billion in 2011, according to a report from IBISWorld. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Genta Incorporated (OTCBB: GNTA) and Cell Therapeutics, Inc. (NASDAQ: CTIC). Access to the full company reports can be found at:

Cell Therapeutics is a biopharmaceutical company engaged in the development, acquisition, and commercialization of drugs for the treatment of cancer. Last week the company announced that The Food and Drug Administration (FDA) set a date of April 24 to decide on CTIC's application for pixantrone -- its treatment for non-Hodgkin's lymphoma.

Cell Therapeutics also said that Pixantrone is under review for marketing approval in Europe, with an opinion by the Committee for Human Medicinal Products tentatively scheduled for Jan. 19.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Genta Incorporated is a biopharmaceutical company engaged in the identification, development, and commercialization of drugs for the treatment of cancer and related diseases. Last week the company announced presentation of results from the Company's Phase 2b clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer.

According to Genta, "Twenty-four patients are currently evaluable for response. Major objective responses (RECIST) have been observed in 50% of patients, including 1 complete response and 11 partial responses. Six of the 12 major responders have cleared more than 75% of their measurable disease. The disease control rate in this study, which includes major responders and patients with stable disease, is 83%."

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at